Literature DB >> 23832820

A new Ki-67 / E-cadherin cocktail reduces inter-observer variation of the calculated proliferative index.

Golan Bubis1, Ohad Hilly, Roy Bubis, Marisa Halpern, Ariel Schwartz, Rumelia Koren, Lea Rath-Wolfson.   

Abstract

The proliferative index in breast carcinoma is usually calculated by the percentage of the Ki-67 positive cells out of the total number of malignant cells. In order to reduce the inter-observer variability of the calculated proliferative index a cocktail of antibodies against E-Cadherin and Ki-67 (Ki/Cad Cocktail) is presented. The cocktail was applied on 59 cases of infiltrating duct carcinoma of breast and compared to the consecutive slides stained for Ki-67 alone. The Ki/Cad cocktail has the advantage that by adding the anti E-Cadherin antibody, all the malignant epithelial cells are highlighted and can be differentiated from other proliferating cells. Statistical analysis proved that the cocktail increases the inter-observer agreement from 89 % to 97 % as compared to the Ki-67 alone and also reduces the overlap between the cancer grades.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23832820     DOI: 10.1007/s12253-013-9655-8

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  19 in total

1.  Comparison of Ki-67 equivalent antibodies.

Authors:  C F Lindboe; S H Torp
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

2.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer.

Authors:  A D Thor; S Liu; D H Moore; S M Edgerton
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

Review 4.  Breast cancer statistics, 2011.

Authors:  Carol DeSantis; Rebecca Siegel; Priti Bandi; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-10-03       Impact factor: 508.702

Review 5.  Ki67 in breast cancer: prognostic and predictive potential.

Authors:  Rinat Yerushalmi; Ryan Woods; Peter M Ravdin; Malcolm M Hayes; Karen A Gelmon
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

6.  E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters.

Authors:  Hina S Qureshi; Michael D Linden; George Divine; Usha B Raju
Journal:  Am J Clin Pathol       Date:  2006-03       Impact factor: 2.493

7.  Evaluation of melanocytic neoplasms: application of a pan-melanoma antibody cocktail.

Authors:  Guy Orchard
Journal:  Br J Biomed Sci       Date:  2002       Impact factor: 3.829

8.  Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer.

Authors:  L Assersohn; J Salter; T J Powles; R A'hern; A Makris; R K Gregory; J Chang; M Dowsett
Journal:  Breast Cancer Res Treat       Date:  2003-11       Impact factor: 4.872

9.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Authors:  Mitch Dowsett; Torsten O Nielsen; Roger A'Hern; John Bartlett; R Charles Coombes; Jack Cuzick; Matthew Ellis; N Lynn Henry; Judith C Hugh; Tracy Lively; Lisa McShane; Soon Paik; Frederique Penault-Llorca; Ljudmila Prudkin; Meredith Regan; Janine Salter; Christos Sotiriou; Ian E Smith; Giuseppe Viale; Jo Anne Zujewski; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2011-09-29       Impact factor: 13.506

10.  Cell proliferation measured by MIB1 and timing of surgery for breast cancer.

Authors:  L S Cooper; C E Gillett; P Smith; I S Fentiman; D M Barnes
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.